Work

Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer

Year: 2018

Type: article

Source: Cancer Chemotherapy and Pharmacology

DOI: 10.1007/s00280-018-3560-5

Authors: Egbert F. Smit, Edward B. Garon, Martin Reck, Federico Cappuzzo, Paolo Bidoli, Roger B. Cohen, Ling Gao, Lisa M. O’Brien, Pablo Lee, Annamaria Zimmermann, David R. Ferry, Allen S. Melemed, Maurice Pérol

Institutions: The Netherlands Cancer Institute, Amsterdam UMC Location Vrije Universiteit Amsterdam, University of California, Los Angeles, German Center for Lung Research, LungenClinic Grosshansdorf, Azienda Ospedaliera San Gerardo, University of Pennsylvania, Eli Lilly (United States), Centre Léon Bérard

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: Eli Lilly and Company

OpenAlex ID: W2799800730

FWCI: 1.527

Cites: 20

Cited by: 23

Related to: 10